W
CLVS

Wealthfront’s Clovis Oncology, Inc. CLVS Stock Holding History

Wealthfront’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5
Closed – – 1154
2015
Q3 		$0 Buy
+5
New +$433 ﹤0.01% 1489

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealthfront's CLVS Position: Q4 2015 in Review

Wealthfront sold out of Clovis Oncology, Inc. (CLVS) in Q4 2015, closing a stake of 5 shares.

Wealthfront first reported a position in CLVS in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 157 funds tracked by Wall St. Rank hold CLVS as of Q4 2015.

  • Wealthfront reported no remaining Clovis Oncology, Inc. position as of Q4 2015 after selling out during the quarter.
  • Wealthfront sold 5 Clovis Oncology, Inc. shares in Q4 2015.
  • Wealthfront first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 1 quarter.
  • Wealthfront's Clovis Oncology, Inc. position peaked at $0 in Q3 2015.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.